Related references
Note: Only part of the references are listed.Molecular biomarkers in urothelial bladder cancer
Wun-Jae Kim et al.
CANCER SCIENCE (2008)
Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor
Eun-Jung Kim et al.
JOURNAL OF UROLOGY (2008)
Molecular origins of cancer: Epigenetics in cancer
Manel Esteller
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Promoter hypermethylation identifies progression risk in bladder cancer
David R. Yates et al.
CLINICAL CANCER RESEARCH (2007)
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells
Amaia Lujambio et al.
CANCER RESEARCH (2007)
Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome
Michael Weber et al.
NATURE GENETICS (2007)
Cancer epigenomics: DNA methylomes and histone-modification maps
Manel Esteller
NATURE REVIEWS GENETICS (2007)
Clinical value of vesical leukoplakia and evaluation of the neoplastic risk by mutation analyses of the tumor suppressor gene TP53
Andrea Staack et al.
INTERNATIONAL JOURNAL OF UROLOGY (2006)
Can the levels of nitric oxide in the urine, serum and tumor tissue be putative markers for bladder cancer?
Sueleyman Kilic et al.
INTERNATIONAL JOURNAL OF UROLOGY (2006)
Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection
Mohammad Obaidul Hoque et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma
Fumiyuki Uematsu et al.
CANCER SCIENCE (2006)
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells
Yoshimasa Saito et al.
CANCER CELL (2006)
Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls
DR Yates et al.
ONCOGENE (2006)
Urothelial cancer biomarkers for detection and surveillance
LS Liou
UROLOGY (2006)
Epigenetic therapy of cancer: past, present and future
CB Yoo et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Spreading of methylation within RUNX3 CpG island in gastric cancer
N Homma et al.
CANCER SCIENCE (2006)
Bladder tumor markers beyond cytology:: International consensus panel on bladder tumor markers
VB Lokeshwar et al.
UROLOGY (2005)
Prognostic markers for bladder cancer:: International consensus panel on bladder tumor markers
T Habuchi et al.
UROLOGY (2005)
RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors
WJ Kim et al.
CANCER RESEARCH (2005)
Urine markers for bladder cancer surveillance: A systematic review
BWG van Rhijn et al.
EUROPEAN UROLOGY (2005)
Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma
JWF Catto et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel
E Dulaimi et al.
CLINICAL CANCER RESEARCH (2004)
Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients
T Tozawa et al.
CANCER SCIENCE (2004)
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients
MG Friedrich et al.
CLINICAL CANCER RESEARCH (2004)
Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer
MG Friedrich et al.
BJU INTERNATIONAL (2003)
Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation
JG Herman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The power and the promise of DNA methylation markers
PW Laird
NATURE REVIEWS CANCER (2003)
Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors
A Giannopoulos et al.
JOURNAL OF UROLOGY (2001)
Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer
SB Baylin et al.
HUMAN MOLECULAR GENETICS (2001)
Bladder tumor antigen assay as compared to voided urine cytology in the diagnosis of bladder cancer
G Priolo et al.
CLINICA CHIMICA ACTA (2001)
p53 immunohistochemistry as a prognostic marker in bladder cancer -: Playground for urology scientists?
BJ Schmitz-Dräger et al.
EUROPEAN UROLOGY (2000)
DNA hypermethylation in tumorigenesis - epigenetics joins genetics
SB Baylin et al.
TRENDS IN GENETICS (2000)
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns
JF Costello et al.
NATURE GENETICS (2000)
Qualitative determination of urinary human complement factor H-related protein (hcfHrp) in patients with bladder cancer, healthy controls, and patients with benign urologic disease
R Heicappell et al.
UROLOGIA INTERNATIONALIS (2000)
Share Paper
